D R Horton Inc vs Zoetis Inc — how do they compare? D R Horton Inc trades at $151.01 (market cap $42.53B), while Zoetis Inc trades at $75.39 (market cap $31.05B). The key difference: D R Horton Inc is the larger of the two by market cap, and Zoetis Inc pays the higher dividend (2.86%). Which is the better fit depends on your goals.
| DHI | ZTS | |
|---|---|---|
Market Cap | $42.53B | $31.05B |
Sector | Consumer Cyclical | Health |
52-Week High | $184.04 | $156.76 |
52-Week Low | $129.82 | $71.91 |
Enterprise Value | $47.25B | $38.35B |
Dividend Yield | 1.2% | 2.86% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Zoetis (ZTS) trades at $75.39, down 0.22% with bearish technical signals and mixed sentiment. The company maintains strong fundamentals with $9.47B revenue, 28.03% net margin, and robust profitability metrics (ROE 67.75%, ROA 18.27%). Recent Q1 2026 earnings missed expectations, while multiple law firms have filed class action lawsuits alleging securities violations between January 2025 and May 2026.
Despite strong financials and analyst consensus price target of $101.43 (34.5% upside), ZTS faces significant legal risks and technical weakness. The stock presents a value opportunity for long-term investors willing to navigate near-term volatility, though the class action lawsuits create substantial uncertainty for shareholder value.
Trailing returns across standard periods
Latest headlines on both assets
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →